Indexado en

Licencia y uso

Citaciones

Cited 11 times in

Altmetrics

Grant support

We thank Ramon M. Pujol, Salvador Aznar-Benitah and Christian Hafner for critical review of prior versions of this paper. This work was supported, in part, by grants from Plan Nacional de I+D (SAF2007-60860 and Consolider ONCOBIO), Ministerio de Ciencia e Innovacion, Madrid, Spain.

Análisis de autorías institucional

Compartir

Somatic oncogenic mutations, benign skin lesions and cancer progression: Where to look next?

Publicado en:Cell Cycle. 7 (17): 2674-2681 - 2008-09-01 7(17), DOI: 10.4161/cc.7.17.6523

Autores: Toll, Agusti; Real, Francisco X

Afiliaciones

Resumen

Somatic oncogenic activating mutations in FGFR3 and/or PIK3CA have recently been described in benign epithelial cutaneous lesions that never progress to malignancy (seborrheic keratoses and epidermal nevi). The same mutations have been observed in malignant neoplasms from other tissues (bladder carcinoma, cervix cancer, colorectal cancer, myeloma). However, many of the above-mentioned epithelial benign cutaneous tumors do not harbour mutations in FGFR3 or PIK3CA. In this review, we focus on new candidate genes for discovery and we outline the potential of the skin as a model to achieve a better understanding of cancer biology.

Palabras clave